About BiondVax

BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax’s go-to-market strategy for its lead candidate M-001, universal flu vaccine is to initially obtain regulatory approval as a primer to a pandemic or seasonal vaccine, and following the accumulation of enough data, to test and gain approval as a universal standalone vaccine.

Learn more about the Flu

We have put together a short movie to help you understand more about the flu virus and how today’s vaccine don’t go far enough in protecting us. Please watch our movie.

BiondVax’s short movie about the flu virus

Our Nasdaq Event

On July 10 we celebrated our recent IPO by ringing the closing bell at the Nasdaq.  Please see our photos & videos from this milestone event.